Market Overview

Valeant Investors Exit Along With Ackman

Share:
Related VRX
Gadfly's Nisen: Valeant's 'Financial Wizardry' Doesn't Change The Long-Term Outlook
Bank Of America, Valeant, Wynn Resorts: Fast Money Picks For March 22
FDA OKs Medicure subsidiary Apicore's generic Xenazine (Seeking Alpha)

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares are trading lower by $1.36 (11 percent) at $10.75 in Tuesday's session. After Monday's close, Bill Ackman of Pershing Square disclosed he has exited the stock after a tortuous 19 months of price action.

At this time, other investors following Ackman's foray into the issue or purchased the issue for other reasons, are also exiting.

After a lower open, Valeant's stock continued lower, far exceeding the former low of the move ($11.36), reaching $10.50. That marks the lowest level for since May 19, 2009, when it bottomed at $10.32.

However, a few contrarian investors (buying when Ackman sells) along with shorts locking in profits have lifted the issue off its lows for the day. As of 10:16 a.m. ET, the rebound off the lows has been capped at $11.04.

See Also: Pershing Square's Valeant Sale Sends 'Untimely Poor Signal'

Posted-In: Technicals Intraday Update Movers Trading Ideas

 

Related Articles (VRX)

View Comments and Join the Discussion!